Application of fibrinogen-420 and its active domain
US9145452B2 · kind B2 · utility
0Cited by
0References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 6, 2013 |
| Grant date | Sep 29, 2015 |
| Priority date | — |
| Expiry date | Sep 6, 2033 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides the uses of fibrinogen-420 or alpha EC domain thereof, for inhibiting protein aggregation, refolding the denatured proteins, manufacturing drugs for prevention and/or treatment of protein misfolding diseases, resisting protein denaturation, and detecting the quality of protein products. The invention also provides the drugs for prevention and/or treatment of protein misfolding diseases or protein denatured disease, and the protein stabilizer. The active ingredient of the said drugs and stabilizer is fibrinogen-420 or alpha EC domain thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.